Abstract: The semiconductor memory device including a bit line in a first direction on a substrate, a channel structure on the bit line, and including a first vertical part in a second direction, and a second vertical part apart from the first vertical part in the first direction and in the second direction, a back-gate electrode on the bit line on a side of the channel structure and in the second direction, a back-gate insulating film between the back-gate electrode and the channel structure, a back-gate capping film on the back-gate electrode and the back-gate insulating film, a first and second word lines between the first and the second vertical parts and in the second direction, the second word line spaced apart from the first word line in the first direction and first and second capacitors connected to the first and second vertical parts, on the first and second vertical parts.

Abstract: The present invention relates to a pharmaceutical composition for treating STK11-mutation cancer, containing, as an active ingredient, a material inhibiting a sodium-potassium transport function of Na+—K+ ATPase (ATP1A1); an anticancer drug containing the composition as an active ingredient; and a method for screening STK11-mutation cancer therapeutic agent. It was first established that, of cancer cells in which various gene mutations are confirmed, an STK11-mutation cancer cell line, which is confirmed at high frequency, was treated with cardiac glycosides as a material inhibiting a sodium-potassium transport function of Na+—K+ ATPase (ATP1A1), to significantly inhibit the growth of cancer cells. Therefore, the material inhibiting a sodium-potassium transport function of Na+—K+ ATPase (ATP1A1) can be a target for treating SK11-mutation-derived cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: Provided are a coupon apparatus, user equipment, a service providing device, a control method thereof, and a non-transitory computer readable storage medium having computer program recorded thereon. That is, according to the present invention, it is possible to issue a coupon in a non-affiliated store and improve convenience of a user by easily issuing the coupon, by issuing the coupon according to a real-time sales situation of the store by a simple operation in a non-affiliated/affiliated store.

Abstract: According to an embodiment of the present invention, a method for issuing a user certificate of a verification server comprises: receiving a user certificate issue request including a user ID from a user terminal; receiving a user public key, a biometric identification replacement code, and hardware identification information generated by the user terminal; and generating a user certificate including the user ID, the user public key, and certificate information; and encrypting the user certificate generated and transmitting it to the user terminal, is provided.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, disorders, or conditions associated with particular c-Jun N-terminal kinase(s) (JNKs) activity are provided. Compositions contain small molecules such as pyrazoloanthrones.